Natera is trading 4.3% up at $407.55 as investors focus on Signatera’s regulatory and clinical progress.
- Japan approved Signatera as a companion diagnostic for muscle-invasive bladder cancer.
- Strong lung-cancer study data reinforced Natera’s oncology growth outlook.
- Shares advanced despite broader market weakness, suggesting company-specific momentum outweighed today’s risk-off environment.